Stronger subsidiary performance and cost control drive earnings
R&D investment hits record high
에볼루션 바카라 사이트 Global (co-CEOs Sung-tae Yoon and Soo-young Song) announced its consolidated financial results for the first quarter of 2025, reporting .3 million in sales, .3 million in operating profit, and .7 million in net profit. These figures represent year-on-year changes of -1.4%, -1.5%, and +13.1%, respectively.
While overall revenue declined slightly, the company cited solid growth in its core businesses—prescription drug sales at 에볼루션 바카라 사이트 and strong aesthetic exports at Humedix—as key contributors to profitability. Operating profit was impacted by increased R&D investments, though SG&A costs were successfully reduced through improved management efficiency.
R&D investment rose by 34% to .7 million, up from .53 million a year earlier. The group attributed the increase to efforts to secure new drug candidates and support clinical trials across 에볼루션 바카라 사이트 and 에볼루션 바카라 사이트lab.
에볼루션 바카라 사이트 (CEO Soo-young Song) posted consolidated sales of 4 million, operating profit of .17 million (+20.1% YoY), and net profit of .81 million (+26% YoY). The company reported strong performance in its ETC (ethical drugs) segment, driven by chronic disease drug growth and increased exports of injectables to the U.S. and eye drops to global markets.
On May 2, 에볼루션 바카라 사이트 received two Abbreviated New Drug Application (ANDA) approvals from the U.S. FDA, adding to its existing portfolio of five approved injectables. The company also maintained a stable performance in its CMO business, supported by high utilization at its second production site.
에볼루션 바카라 사이트’ consolidated operating margin reached 8.8%, while its standalone margin was 9.8%—the highest quarterly margin since 2024. Improved cost management and subsidiary contributions were key to these gains.
Newly launched 에볼루션 바카라 사이트 N, a spin-off focused on health functional foods, reported Q1 sales of .38 million and an operating profit of 3 million. 에볼루션 바카라 사이트LifeSciences significantly narrowed its losses, posting .15 million in sales and a .8 million operating loss.
Humedix (CEO Min-jong Kang), the group’s aesthetic subsidiary, delivered separate 에볼루션 바카라 사이트 of .7 million, operating profit of .16 million (+7.3% YoY), and net profit of .60 million (+45% YoY). Growth was fueled by strong hyaluronic acid (HA) filler exports, particularly to Brazil and newly approved markets like Thailand. Increased API 에볼루션 바카라 사이트 and improved facility utilization also contributed to profitability.
HuM&C (CEO Kim Jun-cheol), which specializes in healthcare components, posted consolidated 에볼루션 바카라 사이트 of .95 million (+4.4% YoY). However, operating profit dropped to 7,000 (-49.6%), and net profit fell to 6,000 (-76.4%). The cosmetics division saw rapid growth with .65 million in 에볼루션 바카라 사이트—up 77.2%—following a recent acquisition. Meanwhile, the glass business posted .30 million in 에볼루션 바카라 사이트. The company expects further growth through its Vietnam production site starting in Q2.
에볼루션 바카라 사이트 BioPharma reported sales of .16 million and an operating profit of .00 million. Despite growth in exports to Thailand and Iraq, a drop in South Korean sales led to a decline in overall performance. 에볼루션 바카라 사이트 Meditech posted .52 million in sales but recorded a 5,000 operating loss due to falling medical device exports. Food Assemble, the group’s meal kit brand, reported .72 million in sales and reduced its deficit with a 0,000 operating loss.
에볼루션 바카라 사이트lab continues clinical development of its human hyaluronidase candidate, ‘HLB3-002’, now in pivotal Phase 1 trials in Korea. The company plans to submit for regulatory approval to MFDS in the second half of the year. At AACR 2025, 에볼루션 바카라 사이트lab presented formulation conversion results for the candidate in a scientific poster session.
에볼루션 바카라 사이트 Global CEO Soo-young Song stated, “에볼루션 바카라 사이트 Group is committed to delivering tangible results through global expansion and sustained R&D investment. We aim to secure long-term growth engines while reinforcing ethical management and legal compliance.”
Chairman Sung-tae Yoon, appointed as CEO by the board during the 38th annual shareholders meeting, has returned to the helm to mark the group’s 60th anniversary. His leadership is focused on global expansion and enhancing pipeline competitiveness through innovation.